Two more deaths reported from Natrecor study

01/3/2006 | ABC News

Johnson & Johnson unit Scios reported two additional deaths occurred during a study of its heart failure drug Natrecor three years ago, but the company said the cases do not indicate increased risk from the drug. A total of seven patients died within 30 days of treatment with Natrecor. The company is preparing a report for the FDA due by April, and the authors of a report on the original study published in the October 2005 issue of the Journal of Emergency Medicine will update their report.

View Full Article in:

ABC News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX